Recursion Reports Third-Quarter 2026 Results and Extends Cash Runway
Recursion also highlighted positive clinical data in REC-4881 and REC-1245, a Sanofi development-candidate option and the appointment of Fred Hassan as chair.
Story updates
09:32:24 PM UTC
SquawkNews
Recursion reported Q3 2026 financial results and clinical updates, including positive REC-4881 Phase 2 data and early REC-1245 data. Sanofi’s development-candidate option triggered a $10M milestone; Recursion says the candidate is expected to enter Phase 1 in 2027.Material DetailsContext by AI Anal…
SALT LAKE CITY, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Recursion NASDAQ:RXRX, a leading clinical-stage company pioneering AI-enabled drug discovery and development, today reported financial results for the third quarter ended September 30, 2026, together with business updates highlighting continued clin…